CLSD News and Press, Clearside Biomedical Inc. From 07/17/25

- Proven In-Office, Repeatable, Non-Surgical Procedure for the Targeted Delivery of a Wide Variety of Therapies for Serious Retinal Diseases - - CLS-AX Phase 3-Ready Asset with Global Investigator Support and FDA Alignment on Pivotal Trial Program in wet AMD - - Validated Delivery...

- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - CLS-AX Combines the Flexibility of Anti-VEGF Therapies with the Long-Lasting Benefits of a Tyrosine Kinase Inhibitor - ALPHARETTA, Ga., June 17, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedi...

2025-06-12 11:03:51 ET Investment Overview Back in January this year, I covered EyePoint Pharmaceuticals, Inc. ( EYPT ) in a note for Seeking Alpha , calling its stock a "risky buy" ahead of a key readout for its lead and only clinical stage drug candidate Du...

ALPHARETTA, Ga., May 21, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS ® ), announced today that management will participate in a ...

2025-05-14 16:13:10 ET More on Clearside Biomedical Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript Clearside Biomedical Q1 2025 Earnings Preview Clearside outlines pivotal Phase 3 plans for CLS-AX in wet AMD Seeking Alpha’...

- Successful End-of-Phase 2 Meeting with FDA Led to Alignment on Phase 3 Program Design for CLS-AX in Wet AMD - - CLS-AX Targets Commercially Attractive Product Profile with Three-to-Six Month Flexible Maintenance Dosing - - Multiple Milestones Achieved by Commercial and Developme...

Aeva Technologies Inc. (AEVA) is expected to report $-0.59 for Q1 2025 Brasilagro Brazilian Agric Real Estate Co Sponsored ADR (Brazil) (LND) is expected to report for Q3 2025 Omron Corporation ADR (OMRNY) is expected to report for Q4 2025 Sezzle Inc. (SEZL) is expected to report $0.3...

2025-05-13 18:48:09 ET Clearside Biomedical, Inc. (CLSD) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 5.06%. The average open to low on the day of earnings was -7.72%. The average ope...

2025-05-13 18:43:09 ET Clearside Biomedical, Inc. (CLSD) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in CLSD stock price following earnings has averaged ±4.44% , with a median of 4.28...

2025-05-13 17:35:54 ET More on Clearside Biomedical Clearside Biomedical, Inc. (CLSD) Q4 2024 Earnings Conference Call Transcript Clearside outlines pivotal Phase 3 plans for CLS-AX in wet AMD Clearside Biomedical GAAP EPS of -$0.10 in-line, revenue of $0.3M beats by...